Facebook
Twitter
LinkedIn
Forward
Optimizing the Recognition and Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes: What Primary Care Clinicians Need to Know
Welcome to our micro-module webcast on the challenges of managing chronic kidney disease (CKD) and diabetes. After diagnosis, slowing CKD progression in type 2 diabetes (T2D) continues to pose a major challenge. Although new therapies, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, have emerged, residual morbidity and mortality persist. Additional strategies are required to slow kidney disease progression, especially targeting inflammation and fibrosis.
This educational activity aims to bridge the gaps in recognizing and treating CKD in T2D patients among healthcare professionals, particularly primary care clinicians and others on the front lines. This micromodule webcast is designed to enhance early screening, diagnosis, and treatment of this condition.
Target Audience
The educational design of this activity addresses the needs of US-based primary care physicians as well as nurse practitioners, nurses, and pharmacists.
Learning Objectives
After completing this activity, the participant should be better able to:
- Review the importance of UACR testing, in addition to eGFR, for the screening and diagnosis of CKD in patients with T2DM
- Identify T2DM patients at risk for CKD or CKD progression based on recommended diagnostic practices
- Summarize comprehensive GDMT approaches to reduce the risk of cardiorenal adverse events in patients with T2DM and CKD
- Recognize the value of regular eGFR and UACR monitoring to guide response to current therapy in patients with CKD and T2DM in order to optimize referral and treatment
Additional Information
George L. Bakris, MD
Professor of Medicine
University of Chicago Medicine
Chicago, IL
Rajiv Agarwal, MD, MS
Emeritus Professor of Medicine
Indiana University School of Medicine and VA Medical Center
Indianapolis, IN
ESTIMATED TIME TO COMPLETE ACTIVITY
1.25 hours
EDUCATIONAL GRANT SUPPORT
Supported by an independent medical educational grant from Bayer HealthCare Pharmaceuticals Inc.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-24-134-H01-P. Type of activity: Application
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 1.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from September 6, 2024 through September 6, 2025.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test(s)
- Complete the activity evaluation
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org. For additional information about the accreditation of this activity, please visit https://partnersed.com
DISCLOSURES
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. Bakris, faculty for this educational activity, discloses the following:
- Consultant: Bayer, Janssen, KBP Biosciences, Ionis, A1
- Executive Committee Clinical Trials: Bayer, KBP Biosciences, Alnylam, Astra Zeneca, Novo Nordisk
Dr. Agarwal, faculty for this educational activity, discloses the following:
- Consultant: Akebia, Boeringer, Bayer, Chinook, Verte
- Adjudication committee: Alnylam, Intercept
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.